Comparing two MRI techniques for detecting significant prostate cancer
A Comparison of the Diagnostic Accuracy of Luminal Index Magnetic Resonance Imaging and Multi-parametric Magnetic Resonance Imaging for the Accelerated Detection of Significant Prostate Cancer
NA · University College, London · NCT05020522
This study is testing a new MRI method to see if it can find significant prostate cancer better than the standard MRI method in men who are already suspected of having the disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 702 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University College, London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT05020522 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the diagnostic accuracy of Luminal Index MRI (LI-MRI) compared to multi-parametric MRI (mpMRI) for detecting clinically significant prostate cancer. LI-MRI is a novel imaging technique that assesses the luminal water fraction in the prostate, potentially allowing for quicker and more accurate detection of cancer. The study will involve men with suspected prostate cancer who are scheduled for mpMRI as part of their routine diagnostic workup, comparing the performance of both imaging methods. Participants will undergo both types of MRI scans to determine which is more effective in identifying significant tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are men with clinically suspected prostate cancer who are referred for prostate MRI.
Not a fit: Patients with a previous diagnosis of prostate cancer or those with high PSA levels may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a more efficient and accurate diagnostic pathway for prostate cancer, reducing unnecessary biopsies and improving patient outcomes.
How similar studies have performed: Preliminary studies have shown promising results for LI-MRI, indicating potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men with clinically suspected prostate cancer and referred for prostate MRI * Willing and able to provide a written informed consent Exclusion Criteria: * Prostate specific antigen (PSA) level \> 20ng/ml within 6 months * Previous diagnosis of prostate cancer * Ongoing hormone treatment within 3 months prior to MRI, excluding antiandrogens or 5-alpha reductase inhibitors * Contraindication to MRI scan * Contraindication to administration of gadolinium-based contrast agents
Where this trial is running
London
- University College London Hospitals NHS Foundation Trust — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Shonit Punwani — University College, London
- Study coordinator: Trial Manager
- Email: ncita.climate@ucl.ac.uk
- Phone: 02076795279
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, Magnetic Resonance Imaging, Luminal Index MRI, Methylation Signature